Gammagard Liquid is a brand-name prescription medication containing concentrated human antibodies, known generically as Immune Globulin Infusion (Human) 10%. Manufactured by Takeda Pharmaceuticals, it is used to treat conditions where the immune system either doesn’t produce enough protective antibodies or is attacking the body’s own tissues. The medication is derived from donated human plasma and delivers a broad mix of antibodies that can fight infections or help regulate immune system activity.
What Gammagard Liquid Treats
Gammagard Liquid is FDA-approved for two main categories of conditions. The first is primary immunodeficiency (PI), a group of disorders where the body can’t make enough antibodies on its own to fight off infections. People with PI are vulnerable to repeated, sometimes severe infections. Gammagard Liquid essentially replaces the missing antibodies, providing the same defense a healthy immune system would.
The second category involves neurological conditions where the immune system mistakenly damages the body’s own nerves. The most well-known of these is chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that causes progressive weakness and impaired sensation in the legs and arms. In CIDP, the immune system strips away the protective coating around nerves. Gammagard Liquid appears to work here through immunomodulatory effects, calming the immune system’s misdirected attack, though the exact mechanism isn’t fully understood.
How It Works in the Body
The active ingredient is immunoglobulin G (IgG), the most common type of antibody in your bloodstream. Gammagard Liquid supplies a wide spectrum of these antibodies, which can neutralize viruses, mark bacteria for destruction, and interact with immune cells to change how they behave. For someone with an immunodeficiency, this is straightforward: the infusion restocks the antibodies their body can’t produce. For autoimmune and inflammatory conditions like CIDP, the mechanism is more complex. The flood of donated antibodies appears to interfere with the processes driving the immune system’s attack on healthy tissue, though researchers haven’t pinpointed exactly how this happens.
Intravenous vs. Subcutaneous Infusion
One feature that sets Gammagard Liquid apart from some other immunoglobulin products is that it can be given two ways: intravenously (into a vein) or subcutaneously (under the skin). The route you use affects how often you receive treatment and where it happens.
Intravenous infusions are typically given every 3 to 4 weeks, usually in a clinic or infusion center, though some patients arrange home infusions with a nurse. The infusion starts slowly and gradually speeds up over the course of the session if you tolerate it well. A single IV session can take several hours depending on the dose.
Subcutaneous infusions are given weekly and can often be done at home after training. The medication is infused through a small needle placed just under the skin, typically in the abdomen, thighs, upper arms, or lower back. Multiple infusion sites may be used at once, spaced at least two inches apart, and sites should be rotated each week. For people weighing 40 kg (about 88 pounds) or more, each site can receive up to 30 mL of fluid. Weekly subcutaneous dosing provides a steadier level of antibodies in the bloodstream compared to the peaks and valleys of monthly IV infusions, which some patients prefer.
What to Expect With Side Effects
Most side effects from immunoglobulin infusions are mild and temporary. Flu-like symptoms are the most common reaction and include flushing, nausea, fatigue, fever, chills, and general malaise. These tend to occur during or shortly after the infusion and resolve on their own. One retrospective study found that nearly 88% of patients experienced some degree of flu-like symptoms during administration.
Headache is particularly common. More than half of patients develop headaches after immunoglobulin infusions. For most people these are manageable, but in rare cases (roughly 0.6 to 1% of patients) immunoglobulin therapy can trigger aseptic meningitis, a more severe form of headache accompanied by neck stiffness, sensitivity to light, and nausea. This resolves with treatment but requires medical attention.
Skin reactions occur in about 6% of patients and are generally mild. With subcutaneous infusions specifically, redness, swelling, or itching at the injection site is common, especially during the first few infusions, and tends to improve over time.
Serious but Rare Risks
Blood clots are the most significant serious risk associated with immunoglobulin therapy, with an estimated incidence of 1 to 17% depending on the study and patient population. Risk factors include older age, prolonged immobility, a history of blood clots, and certain heart or blood vessel conditions. A related concern is hemolysis, where the infused antibodies react with red blood cells, which occurs in roughly 1.6% of patients. Signs include dark urine, unusual fatigue, and shortness of breath. Kidney problems are another recognized risk, particularly with high doses or rapid infusion rates.
Who Receives Gammagard Liquid
Gammagard Liquid is approved for use in adults and children aged 2 and older with primary immunodeficiency. For CIDP, it is approved for adults. The decision to use Gammagard Liquid over other immunoglobulin products often comes down to the flexibility of its two administration routes, since not all competing products offer both IV and subcutaneous options.
For people with PI who switch from IV to subcutaneous dosing, the initial subcutaneous dose is calculated as 1.37 times the previous IV dose, divided by the number of weeks between IV infusions. This adjustment accounts for differences in how the body absorbs the medication through each route. After that, maintenance dosing is fine-tuned based on blood levels and how well you’re responding clinically.
Living With Regular Infusions
Because Gammagard Liquid treats chronic conditions, most people use it on an ongoing basis. IV patients typically commit to a clinic visit every 3 to 4 weeks, with each session lasting several hours. Subcutaneous patients infuse weekly at home, with sessions generally shorter but more frequent. Many patients find that settling into a consistent routine, staying well-hydrated before infusions, and pre-treating with over-the-counter pain relievers helps minimize side effects.
The subcutaneous option has made a meaningful difference for patients who want more independence. After initial training from a healthcare provider, most people can manage their own infusions, which reduces time spent in clinical settings and gives more flexibility in scheduling. Some patients report that the steadier antibody levels from weekly subcutaneous dosing also lead to fewer energy dips compared to the monthly IV cycle.